文献速递乳腺癌

CALGB 40603(Alliance):三阴性乳腺癌新辅助化疗联合或不联合卡铂与贝伐珠单抗的长期结局及应答与生存的基因组相关性

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2022-01-19

CALGB 40603(NCT00861705)为2×2随机II期试验,在II–III期三阴性乳腺癌中评估紫杉醇序贯多柔比星和环磷酰胺基础上加卡铂或贝伐珠单抗;中位随访7.9年,两种药物均未显著改善长期结局,pCR者5年EFS与OS优于有残留病灶者,免疫激活标志与pCR及EFS相关。

要点

  • 加卡铂或贝伐珠单抗虽提高pCR率,但未显著改善长期结局。
  • pCR者5年EFS 85.5% vs 有残留病灶者56.6%,5年OS 87.9% vs 63.4%。
  • 治疗前肿瘤免疫激活标志与更高pCR率和更好生存独立相关。

核心结论

  • 尽管pCR率更高,卡铂与贝伐珠单抗均未改善长期结局,但研究未对其次要终点设把握度。
  • pCR与更优长期结局相关,即使与微小残留病灶相比亦然。
  • 治疗前活检中的免疫激活标志独立关联更高pCR率与更好生存。

研究设计与样本

  • CALGB 40603(NCT00861705)为2×2随机II期试验,443例开始研究治疗的患者纳入长期结局分析。
  • 按临床特征、病理应答、残留病灶者计算的残留癌症负荷(RCB)、治疗分组及周紫杉醇(wP)期间剂量实施评估长期结局。
  • 治疗前肿瘤样本经mRNA测序评估治疗应答与结局的基因组预测因素。

主要发现

  • 中位随访7.9年,卡铂或贝伐珠单抗均未显著改善长期结局,总体及经基因组分析确定的基底样亚型患者中均如此。
  • pCR者(n=205,46.3%)5年EFS为85.5% vs 有残留病灶者56.6%(log-rank P<.0001)。
  • pCR者5年OS为87.9% vs 有残留病灶者63.4%(P<.0001)。
  • 基线特征中仅临床分期与长期结局相关。
  • 免疫激活证据(包括肿瘤浸润淋巴细胞和低B细胞受体不均一性)与pCR及改善的EFS相关。

局限性

  • 研究未对长期结局这些次要终点设把握度(not powered to assess these secondary end points)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now report long-term outcomes (LTOs) and correlative science end points. PATIENTS AND METHODS: The Kaplan-Meier method was used to estimate LTOs in 443 patients who initiated study treatment. Log-rank tests and Cox proportional hazards models evaluated the impact of clinical characteristics, pathologic response, calculated residual cancer burden (RCB) in patients with residual disease (RD), treatment assignment, and dose delivery during wP on LTOs, including event-free survival (EFS). Genomic predictors of treatment response and outcomes were assessed on pretreatment tumor samples by mRNA sequencing. RESULTS: Among baseline characteristics, only the clinical stage was associated with LTOs. At a median follow-up of 7.9 years, LTOs were not significantly improved with either carboplatin or bevacizumab, overall or in patients with basal-like subtype cancers by genomic analysis. Patients with pCR (n = 205, 46.3%) had significantly higher 5-year EFS (85.5% v 56.6%, log-rank P < .0001) and overall survival (87.9% v 63.4%, P < .0001) rates compared with patients with RD, even those with RCB class I. Among clinical and genomic features, evidence of immune activation, including tumor-infiltrating lymphocytes and low B-cell receptor evenness, was associated with pCR and improved EFS. CONCLUSION: Despite higher pCR rates, neither carboplatin nor bevacizumab appeared to improve LTOs although the study was not powered to assess these secondary end points. pCR was associated with superior LTOs even when compared with minimal RD. Markers of immune activation in pretreatment tumor biopsies were independently associated with higher pCR rates and improved survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shepherd JH, Ballman K, Polley MC, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022. PMID: 35044810. doi:10.1200/JCO.21.01506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。